NMBA Related License Agreement - Additional Information (Details) - Cornell University - Neuromuscular Blocking Agents License Agreement |
1 Months Ended |
|---|---|
|
Jun. 30, 2017
USD ($)
| |
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |
| Acquired IPR&D | $ 766,000 |
| Upfront payment obligation | 350,000 |
| Operational liabilities and acquisition-related costs | $ 416,000 |
| Acquired IPR&D charge expected deductible period for income tax purposes | 15 years |
| U.S | |
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |
| Regulatory approval and commercialization milestones | $ 5,000,000 |
| European | |
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |
| Regulatory approval and commercialization milestones | $ 3,000,000 |
| X | ||||||||||
- Definition Asset acquisition, in process research and development charge, expected tax deductible period. No definition available.
|
| X | ||||||||||
- Definition Asset acquisition, in process research and development charges. No definition available.
|
| X | ||||||||||
- Definition Asset acquisition operational liabilities and acquisition related costs. No definition available.
|
| X | ||||||||||
- Definition Asset acquisition upfront payment obligation. No definition available.
|
| X | ||||||||||
- Definition Maximum regulatory approval and commercialization milestone payments. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|